Home>>Signaling Pathways>> Microbiology & Virology>> Entry/Fusion Inhibitors>>TC 14012 (trifluoroacetate salt)

TC 14012 (trifluoroacetate salt)

Catalog No.GC45004

C-X-C chemokine receptor type 4 (CXCR4) is a receptor for the stromal cell-derived factor-1 which is designated as chemokine ligand 12 (CXCL12).

Products are for research use only. Not for human use. We do not sell to patients.

TC 14012 (trifluoroacetate salt) Chemical Structure

Size Price Stock Qty
1mg
$170.00
In stock
5mg
$763.00
In stock
10mg
$1,358.00
In stock

Tel:(909) 407-4943 Email: sales@glpbio.com


Customer Reviews

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

C-X-C chemokine receptor type 4 (CXCR4) is a receptor for the stromal cell-derived factor-1 which is designated as chemokine ligand 12 (CXCL12). It is involved in cell progression, hematopoiesis, cancer, HIV entry, and rheumatoid arthritis. TC 14012 is an antagonist of CXCR4, blocking CXCR4-mediated HIV infection with an IC50 value of 19.3 nM. In addition, TC 14012 (100 μg/ml) inhibits CXCL12-induced phosphorylation of p42/44 MAPK and STAT3 in B cells from patients with chronic lymphocytic leukemia. This peptidomimetic is C-terminally amidated, resulting in high stability in serum. TC 14012 also activates CXCR7 (EC50 = 350 nM), resulting in the recruitment of β-arrestin and Erk ½ phosphorylation.

Reviews

Review for TC 14012 (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 13 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TC 14012 (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.